Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies

Table 2 Effect of primary biliary cholangitis therapy on fatigue and pruritus

Therapy	Effect on fatigue	Effect on pruritus
UDCA[43,45]	No significant improvement2	Often insufficient2
OCA[70,92]	No improvement2	Worsening or new-onset, dose-dependent3
Fibrates[84]	Mild to moderate improvement1	Clinically meaningful reduction1
Elafibranor[95]	Mild to moderate improvement1	Clinically meaningful reduction1
Seladelpar[98]	Mild to moderate improvement1	Significant reduction1
Budesonide[108]	Little or no documented effect2	Marginal or no specific effect2
IBAT inhibitors (e.g., linerixibat, maralixibat)[107]	Data limited	Marked improvement1

¹Improvement.

²No meaningful change.

³Worsening or increase.

UDCA: Ursodeoxycholic acid; OCA: Obeticholic acid; IBAT: Ileal bile acid transporter.